Sugi Predict

Sugi Predict / Compounds / SCHEMBL597355

SCHEMBL597355

SCHEMBL597355

CN(C)c1cccc2c(S(=O)(=O)NCCCC[C@H](N)C(=O)O)cccc12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC4 P56524 1/20 0.64
▸ HDAC10 Q969S8 1/20 0.64
▸ HDAC6 Q9UBN7 1/20 0.64
▸ HDAC5 Q9UQL6 1/20 0.64
▸ GBA1 P04062 3/20 0.54
▸ GLB1 P16278 3/20 0.54
▸ FUCA1 P04066 1/20 0.54
▸ TGM2 P21980 3/20 0.52
▸ MEN1 O00255 1/20 0.51
▸ GMNN O75496 1/20 0.51
▸ ALDH1A1 P00352 1/20 0.51
▸ LMNA P02545 1/20 0.51
▸ MAPT P10636 1/20 0.51
▸ BLM P54132 1/20 0.51
▸ PMP22 Q01453 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ HTR1A P08908 2/20 0.50
▸ PTGS2 P35354 1/20 0.50
▸ NPC1 O15118 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29358078 1.00 HDAC4 (0.64) HDAC4HDAC10HDAC6HDAC5GBA1
SCHEMBL13651429 1.00 HDAC4 (0.64) HDAC4HDAC10HDAC6HDAC5GBA1
SCHEMBL9163130 0.92 HDAC4 (0.58) HDAC4HDAC10HDAC6HDAC5GBA1
SCHEMBL14110754 0.86 HDAC4 (0.62) HDAC4HDAC10HDAC6HDAC5GBA1
SCHEMBL4146037 0.86 HDAC4 (0.62) HDAC4HDAC10HDAC6HDAC5GBA1
SCHEMBL12707627 0.86 HDAC4 (0.53) HDAC4HDAC10HDAC6HDAC5GBA1
SCHEMBL13911551 0.85 HDAC4 (0.55) HDAC4HDAC10HDAC6HDAC5GBA1
SCHEMBL869336 0.85 HDAC4 (0.55) HDAC4HDAC10HDAC6HDAC5GBA1
SCHEMBL29462219 0.85 HDAC4 (0.55) HDAC4HDAC10HDAC6HDAC5GBA1
SCHEMBL29936015 0.85 HDAC4 (0.55) HDAC4HDAC10HDAC6HDAC5GBA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 283 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1594962-B1 COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS PROMEGA CORP (US) 2014-08-27 — — EP claimed
EP-2369006-B1 Covalent tethering of functional groups to proteins PROMEGA CORP (US) 2014-03-12 — — EP claimed
EP-1007570-B1 MONOSPECIFIC ANTIBODY REACTIVE WITH FIBRINOGEN AND FIBRINOPEPTIDE B NEW YORK BLOOD CT INC (US) 2009-06-10 — — EP claimed
US-20040082499-A1 Perturbed membrane-binding compounds APOSENSE LTD. (IL) 2004-04-29 — — US claimed
US-5541633-A Ink jet printing of concealed images on carbonless paper XEROX CORPORATION (US) 1996-07-30 — — US claimed
US-5286286-A Containing diethylene glycol monobutyl ether, glycerol, and a dansyl or porphyrin chromophores XEROX CORPORATION (US) 1994-02-15 — — US claimed
US-20250188510-A1 ENHANCEMENT OF KINASE TARGET ENGAGEMENT PROMEGA CORPORATION 2025-06-12 — — US disclosed
US-12221648-B2 Substrates for covalent tethering of proteins to functional groups or solid surfaces PROMEGA CORPORATION (US) 2025-02-11 — — US disclosed
US-12078634-B2 Broad spectrum kinase binding agents PROMEGA CORPORATION (US) 2024-09-03 — — US disclosed
EP-4204808-A1 TARGET ENGAGEMENT ASSAY FOR RAS PROTEINS Promega Corporation (US) 2023-07-05 — — EP disclosed
US-20230194515-A1 BROAD SPECTRUM KINASE BINDING AGENTS PROMEGA CORPORATION 2023-06-22 — — US disclosed
US-11667648-B2 Cell-permeable, cell-compatible, and cleavable linkers for covalent tethering of functional elements PROMEGA CORPORATION (US) 2023-06-06 — — US disclosed
EP-4153770-A2 ENHANCEMENT OF KINASE TARGET ENGAGEMENT Promega Corporation (US) 2023-03-29 — — EP disclosed
WO-1998047002-A2 POLYVALENT PRESENTER COMBINATORIAL LIBRARIES AND THEIR USES ADVANCED MEDICINE, INC. (US) 1998-10-22 — — WO disclosed
EP-0590145-B1 FIBER OPTIC SENSOR AND METHODS FOR DETECTING AN ORGANIC ANALYTE IN A FLUID OR VAPOR SAMPLE TUFTS COLLEGE (US) 1998-09-02 — — EP disclosed
US-5714327-A PLATINUM CONTAINING DETECTABLE PROBE COMPOUND HAVING MARKER MOIETY, STABILIZING SUBSTITUENTS, BIOMOLECULE KREATECH DIAGNOSTICS (NL) 1998-02-03 — — US disclosed
US-5643722-A MARKING PROTEINS AND DETECTION, INCUBATION TRUSTEES OF BOSTON UNIVERSITY 1997-07-01 — — US disclosed
US-5541633-A Ink jet printing of concealed images on carbonless paper XEROX CORPORATION (US) 1996-07-30 — — US disclosed
EP-0465124-B1 Ink compositions XEROX CORP (US) 1994-08-10 — — EP disclosed
US-5286286-A Containing diethylene glycol monobutyl ether, glycerol, and a dansyl or porphyrin chromophores XEROX CORPORATION (US) 1994-02-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230194515-A1 BROAD SPECTRUM KINASE BINDING AGENTS MAP4K2, MAP3K20, MAP4K1 HDAC4 2808/4885HDAC10 1714/4885HDAC6 1410/4885
US-11667648-B2 Cell-permeable, cell-compatible, and cleavable linkers for covalent tethering of functional elements LNPK, EPCAM, AFG3L2 HDAC4 2544/4885HDAC10 3222/4885HDAC6 1480/4885
US-12078634-B2 Broad spectrum kinase binding agents MAP4K2, MAP3K20, MAP4K1 HDAC4 2808/4885HDAC10 1714/4885HDAC6 1410/4885
US-20040082499-A1 Perturbed membrane-binding compounds PEBP1, VAPB, MBOAT1 HDAC4 3776/4885HDAC10 3789/4885HDAC6 3135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.